06 February 2024
06 February 2024
Novo Holdings announced a merger agreement with Catalent, selling three manufacturing facilities to Novo Nordisk.
The US Department for Health and Human Services (HHS) released new research that highlights US prescription drug prices are nearly triple those of 33 other Organisation for Economic Co-operation and Development (OECD) countries.
The Chiesi Group gained access to MYALEPTA through the acquisition of Amryt Pharma in April 2023.
AnaMar’s AM1476 received orphan drug designations from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), with the Swedish biotech now planning a Phase II trial.
MorphoSys is entitled to a one-time payment of $25m from Incyte.
The company filed an application seeking investigational new drug (IND) approval for the asset in November 2023.
J&J’s nipocalimab met primary endpoints in Phase III and II trials for myasthenia gravis and Sjogren’s disease, respectively.
Valneva will use the voucher sale funds for R&D projects, including a Lyme disease vaccine being co-developed with Pfizer.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
